UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 11, 2016

Interpace Diagnostics Group, Inc. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 000-24249 (Commission File Number) 22-2919486 (IRS Employer Identification No.)

Morris Corporate Center 1, Building A 300 Interpace Parkway Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

(862) 207-7800

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Interpace Diagnostics Group, Inc. (the "Company") is furnishing an Investor Presentation (the "Investor Presentation"), attached hereto as Exhibit 99.1, which the Company may use from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the Company's investor relations webpage at http://www.interpacediagnostics.com.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Investor Presentation dated January 2016 (furnished and not filed for purposes of Item 7.01)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Interpace Diagnostics Group, Inc.

Date: January 11, 2016

By: /s/ Graham G. Miao

Graham G. Miao Executive Vice President, Chief Financial Officer, Treasurer and Secretary

EXHIBIT INDEX

 EXHIBIT
 DESCRIPTION

 99.1
 Investor Presentation dated January 2016 (furnished and not filed for purposes of Item 7.01)

Exhibit 99.1



Investor Presentation

January 2016

NASDAQ

IDXG

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to our future financial and operating performance. The company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," 'will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond company's control. These statements are based on current risks, uncertainties and other factors that may cause company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to adequately finance the business, the market's acceptance of our molecular diagnostic tests; our ability to secure additional business and generate higher profit margins through sales of our molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the company's periodic filings with the Securities and Exchange Commission (SEC), including without limitation, the Annual Report on Form 10-K filed with the SEC on March 5, 2015 and in the company's Form 10-Q filed with the SEC on November 12, 2015. Because of these and other risks, uncertainties



Investment Highlights

- Interpace Diagnostics (IDX) was formerly part of PDI that had both IDX and Commercial Services (CSO) businesses. PDI was renamed Interpace Diagnostics Group after the sale of CSO in December 2015
- Focused on developing and marketing molecular based diagnostic tests in high value precision pre-cancerous test markets
- · Three proprietary cancer molecular tests on the market in GI and Endocrine
 - PancraGen[™] The new standard of pancreatic cyst diagnostics
 - ThyGenXTM and ThyraMIRTM Next-Gen sequencing oncogene panel and miRNA classifier in combination to improve risk classification of Thyroid nodules

- Two state of the art CLIA-certified labs
- Additional pipeline tests under development including BarreGen[™] for Barrett's Esophagus, an esophageal cancer risk classifier
- · Addressable potential market opportunity of \$2.7 billion with all four tests
- Revenue of approximately \$10 million in 2015, supported by IDX sales forces
- Focus for 2016: Grow recently launched ThyGenX/ThyraMIR tests and expand PancraGen market penetration



Our Mission



Providing personalized medicine through Molecular Diagnostics to advance patient care based on rigorous science.



Interpace Diagnostics Key Milestones

AUGUST 2014:	Acquired Thyroid Assets from Asuragen
OCTOBER 2014:	Acquired RedPath Inc., GI assets and CLIA lab
DECEMBER 2014:	Launched ThyGenX [™] NextGen Sequencing Thyroid Cancer Test
FEBRUARY 2015:	Published landmark study on <i>PancraGen</i> ™ in Endoscopy
APRIL 2015:	Launched ThyraMIR [™] microRNA Gene Expression Thyroid Cancer Test
MAY 2015:	Published the major clinical validation study in JCEM for combining ThyGenX and ThyraMIR in a single testing service
MAY 2015:	Published BarreGen [™] BASE study on Barrett's Esophagus cancer risk progression in AJG
AUGUST 2015:	Covered lives for Interpace Diagnostics products exceeded 100 million for all tests combined
OCTOBER 2015:	Data presented at ACG demonstrate that <i>PancraGen</i> [™] can improve detection of malignant or highly aggressive pancreatic cysts over current guidelines criteria, and improve patient outcomes in real life management decisions
	New data presented at ATA further validates the power of combination testing by $ThyGenX^{\mathbb{W}}$ and $ThyraMIR^{\mathbb{W}}$, improving the preoperative diagnosis of thyroid nodules with indeterminate cytology
DECEMBER 2015:	PDI transformed into Interpace Diagnostics Group through the sale of its CSO business to focus exclusively on molecular diagnostics



Interpace Diagnostics Focus

High Value Molecular Pre-Cancerous Test Market

- 1. High barrier to entry due to complexity of tests and intellectual know how
- 2. Pre-cancerous diagnosis and prognosis focus where test pricing is higher
- 3. Highly complex messaging to HCPs is a capability

Our Commercial Expertise Aligns with Dynamics of Molecular Diagnostics Market



Our Marketed Molecular Tests




Current U.S. Market Opportunity





.....







Thyroid Nodules

Common clinical problem


-10-18 m US Adults have nodules Estimated 525,000 thyroid FNA per year in US and growing





*American Cancer Society

Thyroid Cancer Incidence*



Thyroid Surgery

Significant Surgical Risks

- Large incision in sensitive area and potential for significant scarring
- Risk of vocal cord damage, hoarseness, paralysis, and at the extreme, tracheotomy





Guideline Recommendations

Molecular Markers/Diagnostic Testing



National Comprehensive Cancer Network^{*}

2013 NCCN Guidelines

Molecular Diagnostics recommended testing on some indeterminate cytologies to minimize unnecessary surgeries



2014 American Thyroid Association Revised Guidelines

MDx Tests should be considered for suspicion of malignancy or indeterminate.



Source: Cooper DS et al. Thyroid. 2009;19(11):1167-1214; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. V.1.2014; ATA Guidelines on Thyroid Nodules and Differentiated Thyroid Cancer – Highlights, Consensus, and Controversies. ICE/ENDO conference; June 21-24, 2014; Chicago, Illinois.

Improving Thyroid Cancer Diagnosis

Use of Molecular Markers

Molecular diagnostic tests help the diagnosis of thyroid cancer when cytology is indeterminate

CURRENTLY 2 MAIN PLATFORMS:

- 1. Mutation/Genetic Testing "Rules-In" Cancer
 - Highly specific
 - ThyGenX™


(BRAF*, KRAS, HRAS*, NRAS*, RET/PTC1*, RET/PTC3, PAX8/PPAR-^{3*}, PIK3CA, over 100 reportable markers)

- 2. Gene Expression "Rules-Out" Cancer
 - Highly sensitive
 - Veracyte Afirma GEC
 - ThyraMIR ™





ThyGenX[™] Pathway for Thyroid Cancer Diagnosis



ThyGenX + ThyraMir offers superior solution

	Veracyte Afirma ¹	ThyGenX ThyraMIR ²
Characterize Malignancy	No	Yes
Prominent Results	Likely Benign	Benign/Malignant
PPV	47%	74%
NPV	92%	94%
Diagnostic Yield *	41%	67%
Sample Collection	Dry Ice	Room Temperature


* Diagnostic Yield is defined as % true benign that are called benign using each essay

ThyGenX/ThyraMIR testing provides 65% increase in true benign calls and 69% decrease in the number of unnecessary surgeries on benign nodules, relative to mRNA gene expression classifier (p<0.01)

INTERPACE
 1. Alexander et al. NEJM 367:8, 2012; 2. Labourier et al. J.Clin Endocrinol Metab 2015 May 12 [Epub]

ThyGenX +ThyraMIR

Combined Rule-in and Rule-out in a single testing service to better inform treatment decision




Source: Molecular testing for miRNA, mRNA and DNA on fine needle aspiration improves the pre-operative diagnosis of thyroid nodules with indeterminate cytology. J.Clin Endocrinol Metab 2015 May 12 (Epub ahead of print)

Thyroid Franchise Go-to-Market Strategy

Robust Science	·	Published the major clinical validation study for ThyGenX & ThyraMIR in JCEM – the first Rule-in and Rule-out thyroid cancer test in a single testing service
		Additional study in development
	ŀ	Expanded sales force in early 2015
Commercial		Launched ThyGenX 12/2014 and ThyraMIR 4/2015
Execution		Deploy established commercial capabilities
		 Marketing Campaign and Messaging
		 Medical Education and Patient Advocacy
Coverage and	ŀ	ThyGenX covered by Medicare LCD; ThyraMIR in preparation for Medicare LCD
Reimbursement	ŀ	Over 90 million lives covered for ThyGenX including Aetna
	•	A major regional BCBS recently issued coverage for both ThyGenX and ThyraMIR

Thyroid Tests - Payor Type and Coverage



DIAGNOSTICS


- ThyGenX under Medicare LCD; ThyraMIR Medicare LCD application in progress
- A major regional BCBS coverage for both ThyGenX and ThyraMIR
- Over 90 million lives covered for ThyGenX including Aetna





Pancreatic Cancer:

The Fourth Leading U.S. Cancer Killer



- 5-year survival rate 7.2%
- Pancreatic cancer 3% of new cancer cases in US, 12% of deaths of common cancers



Source: ACS Cancer Facts & Figures 2014; all figures annual

120,000 Pancreatic Cysts Annually

The clinical dilemma:

- Current guideline tests are unreliable and poorly predict cancer risk
 - Cyst fluid tested for CEA, amylase, and cytology (1st line tests)

Pancreatic cysts:

2-5%

risk of cancer increasing with age¹

The result:

- 80% of all surgeries are for benign disease
 - Unnecessary healthcare costs
 - High morbidity (30%) and mortality (2%)² associated with these surgeries
- Pancreatic cancers go undetected

Pancreatic cysts:

80%

surgeries are benign



Source: ¹Gatroenterology Research and Practice Volume 2012, Article 147465 ²Gastroenterology 2015; 148:819-822

PancraGen[™] Powered by PathFinderTG[®]

90% Accuracy At Predicting Malignant Pancreatic Cysts

Multi-faceted algorithm-based platform

- 1. Oncogene mutations (KRAS, GNAS) and 15 markers
- 2. DNA quantification
- 3. Loss of heterozygosity
- 4. CEA & Amylase biomarkers
- 5. Cytology results



Substantial Improvement Over Guidelines

Results published in leading GI journal, Endoscopy


Performance of all patients (n=492)	PancraGen™	ICG Sendai Guidelines	<i>P-</i> Value		
Accuracy	90%	52%	N/A		
Specificity	91%	46%	<0.0001		
PPV	58%	21%	<0.0001		
NPV	97%	97%	0.88		
Sensitivity	83%	91%	0.17		



Source: Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts, *Endoscopy*. 2015 Feb 47(2): 136-46. Epub 2014 Oct.

PancraGen[™] Powered by PathFinderTG[®]

Pancreatic Cysts: Clinical Validity and Utility



PFTG provides an effective strategy of risk stratification of malignancy for optimal patient care



Source: Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts, *Endoscopy*. 2015 Feb 47(2): 136-46. Epub 2014 Oct.

PancraGen More Accurately Predicts Malignant **Pancreatic Cysts**

Results published in leading GI journal, Endoscopy

- 84% of the patients recommended for surgery by Sendai were benign or indolent
- PancraGen may reduce unnecessary surgeries by 66%
- Patients with "aggressive" PancraGen diagnosis were 76 times more likely to progress to malignancy




Source: Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts, *Endoscopy*. 2015 Feb 47(2): 136-46. Epub 2014 Oct.

PancraGen Go-to-Market Strategy

Robust Science	 Published National Pancreatic Cyst Registry study in <i>Endoscopy</i> 2015 Published health economic and outcome
	study in Endoscopy International Open 2015
	 PancraGen is the most cost effective strategy in patient management
Commercial Execution	 Deploy established commercial capabilities Marketing Campaign and Messaging Medical Education and Patient Advocacy
Coverage and Reimbursement	 Reimbursement by Medicare LCD (\$3,100/test); Permanent LCD expected in Q4 2015
	 Over 70 million lives covered including managed care plans


PancraGen - Payor Type Mix and Coverage



*Payer mix % based on claim submissions; May vary by month




- Medicare LCD
 reimbursement at \$3100
- Updated LCD eliminates previous "evidence development" coverage condition
- Over 70 million lives covered including Medicare and managed care plans






What is Barrett's Esophagus?



- Gastroesophageal reflux very common (10-20% US adults)
- 6% progress to Barrett's Esophagus (~3.3 million adults)
- Barrett's Esophagus precedes esophageal cancer (EAC) infrequently (1-2%)
- Ablation (Barrx) has emerged as a treatment and prevention strategy
- Current tests cannot predict which patients will progress to EAC – a high unmet need for a molecular diagnostic test



BarreGen for Barrett's Esophagus






Source: Company estimates

BarreGen for Barrett's Esophagus

Barrett's is currently diagnosed by pathology





BarreGen™


Esophageal Cancer Risk Classifier

- Millions in US undergo expensive, unnecessary procedures to prevent EAC
- Growing evidence that Barrett's recur post-ablation (est. 20+%) and the recurrence may create more aggressive disease state
- BarreGen determines risk of progression from Barrett's to cancer prior to the onset of HGD or EAC
 - · Early detection and prevention of cancer
 - Avoidance of unnecessary interventions with undesirable side effects
 - · Reduction in healthcare costs



BarreGen[™] Clinical Results

Results of BASE study published in Am J. Gastroenterol (AJG)



- 1. Case-control study N= 69 patients (46 controls and 23 cases).
- Mutational load (ML) to measure genetic instability (LOH) associated with tumor suppressor genes
- Based on ML score, BarreGen predicts risk of BE for future progression to cancer



Source: The presence of genetic mutations at key loci predicts progression to Esophageal Adenocarcinoma in Barrett's Esophahus. *Am J. Gastroenterol.* 2015 June 110(6): 828-34. Epub 2015 May


BarreGen[™] - Multi-stage Introduction

- Clinical experience program initiated Q4 2015
 - Scientific advisory board and select KOLs
- Soft launch planned in 2016
 - Prognostic value in determining cancer progression risk
 - BASE study Eluri 2015¹ (n=69)
 - Diagnostic value in detecting true dysplasia (HGD) in BE
 - Ellsworth 2012 study² (n=271) and Khara 2014 study³ (n=415)
- Additional clinical studies underway
 - Interim results of the on-going BELONG study are inconclusive but suggest that alternative tissue fixation methodology may of value to improve BarreGen performance for mutation detection
- Establish collaborations with Barrett's Center of Excellence



¹ Eluri et al. Am J Gastroenterology 2015, 110:828-834
 ² Ellsworth et al. BMC Gastroenterology 2012, 12:181
 ³ Khara et al. J. Gastrointestinal Cancer 2014 DOI 10.1007/s12029-013-9570-y

Number of Molecular Tests Ordered Rising




Total Molecular Tests Ordered

Total Molecular Tests include PancraGen and Thyroid Tests



Number of Thyroid Tests Ordered Growing



Total Thyroid Molecular Tests Ordered

Total Thyroid Molecular Tests include ThyGenX and ThyraMIR



Appendix



MDx Market Shares (%) by Sector

The Fastest Growing Segment is Oncology





Source: Visiongain2014

Current Pancreatic Cysts Guidelines

Sendai guidelines 2012 and ACG guidelines 2007 strongly favor surgical resection because of the inability of first-line tests to predict biological behavior and aggressiveness.

PancraGen[™] establishes a new standard for the prognosis and diagnosis of pancreatic cysts



PancraGen[™] Powered by PathFinderTG[®]

Clinically Validated

- Over 25,000 clinical cases analyzed
- Over 200 peer-reviewed articles





Clinical Meaningful and Actionable Results

	Example Report: PFTG Pancreas					
	PANCRAGEN			SUMMARY REPORT Powered by PathFinderTG *		
	MRN: 00-12 DOB - Age - Sex: 01/01	LIC, JANE Q 23456 1/1950 • 63 yrs • Female 5, Mark M	Interpace 0	Diagnostics Accessio Case Accessio Specimen Recei External Accessio	ned: 01/23/2015 ved: 01/02/2015	
	Specimens Received 1. Buccal Brush (Ext Part 1; Col 2. Pancreatic Body Cyst Fluid ()		01/2015)	Documents R Cytology Report EUS Report, P Pathology Rep	rt ancreas	
	INTEGRATED DIAGNOSIS					
PFTG Diagnosis	 Biological Behavior 	Benign This Patient	Statistically Indolent	Statistically Higher Risk	Aggressive	
	MOLECULAR RESULTS					
	DNA Quantity DNA Quality Oncogene Point Mutations	Low Poor				
Patient management	KRAS Point Mutati GNAS Point Mutati					
-	 Tumor Suppressor Genes (LCH) No LOH det				
recommendations	NON-MOLECULAR RESULTS Pancreatic Cyst Fluid					
Based on patient outcome data	AccuCEA Amylase	less than 0.3 152 U/L	ng/mL			
	COMMENT	102.012				
 Provided by board certified 	The biological behavior of this p					
anatomical pathologists	Please note that, because cysti multifocal areas of heterogenec pathology. Clinical correlation a possibility.	ous pathology, sampling	variation may occas	sionally result in under	diagnosis of existing	
	Notwithstanding the benign mol large size of the cystic process, both clinical and molecular anal subsequent findings with the in determined.	One approach to be con lyses of this cyst, if future	nsidered is to repeat a clinical follow-up a	t the imaging and/or a warrants additional stu	spiration and perform des. By comparing	
	INTERPRETED BY					
				January 28, 2015		
	Sydney D. Finkelstein, MD		_	Date		
1 OINTEDDACE	Medical Director	interpaced agrostics.com			Summary Report - Page 1 of	

New Thyroid Cancer Detection Paradigm

Combined Rule-in and Rule-out cancer in a single testing service to better inform treatment decision

